Since PD-L1 protein undergoes degradation in cancer cells in response to the drugs gefitinib13, curcumin22, metformin21, and etoposide23 when combined with anti-PD-1, anti-CTLA4, or anti-Tim3 antibody, we observe that combination therapy effectively improves tumor immunotherapy (Table 2). Here, CD274 is linked to neoplasm.